RM-MET / Metabolic and incretin signalling
Semaglutide
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
A GLP-1 receptor agonist peptide used in FDA-approved products. Extensively studied as a finished pharmaceutical; that literature describes the approved presentation.
Evidence position
Grade A. An approved comparator exists. Do not read approval of a finished drug as evidence about separately sourced material.
What the record does not establish
Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.
Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.
Sources
- 01Wegovy prescribing informationFDA Access Data
- Shows
- Approved label for the finished product
- Does not show
- Describes the approved product only
- 02STEP 1 phase 3 trialPubMed
- Shows
- Human interventional data
- Does not show
- Studied the approved presentation
- 03FDA concerns with unapproved GLP-1 drugsU.S. Food and Drug Administration
- Shows
- Regulator position on unapproved GLP-1 products
- Does not show
- Not compound-specific quality data
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Semaglutide
- CID
- 56843331
- Formula
- C187H291N45O59
- Mass
- 4114
PUBMED / FOUND RECORDS
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet (London, England) / 2021 Mar 13PMID 33667417 / DOI 10.1016/S0140-6736(21)00213-0
- Safety of Semaglutide.Frontiers in endocrinology / 2021PMID 34305810 / DOI 10.3389/fendo.2021.645563
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.Journal of the ASEAN Federation of Endocrine Societies / 2022PMID 36578889 / DOI 10.15605/jafes.037.02.14
- Semaglutide lowers body weight in rodents via distributed neural pathways.JCI insight / 2020 Mar 26PMID 32213703 / DOI 10.1172/jci.insight.133429
- The Discovery and Development of Liraglutide and Semaglutide.Frontiers in endocrinology / 2019PMID 31031702 / DOI 10.3389/fendo.2019.00155
CLINICALTRIALS.GOV / FOUND RECORDS
- Lifestyle Counseling and Medication for Adolescent Weight ManagementCOMPLETED / PHASE2 / University of MinnesotaNCT04873245 / DIRECT intervention MATCH: Semaglutide
- Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 DiabetesCOMPLETED / PHASE4 / University of Erlangen-Nürnberg Medical SchoolNCT05303857 / DIRECT intervention MATCH: Semaglutide
- A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityCOMPLETED / PHASE1 / Novo Nordisk A/SNCT04187300 / DIRECT intervention MATCH: Semaglutide
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesCOMPLETED / PHASE3 / Eli Lilly and CompanyNCT05822830 / DIRECT intervention MATCH: Semaglutide
- A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After MenopauseCOMPLETED / PHASE1 / Novo Nordisk A/SNCT05153564 / DIRECT intervention MATCH: Semaglutide